We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Nasdaq Real Time Price USD

SciSparc Ltd. (SPRC)

0.2468

-0.0012

(-0.48%)

As of 12:48 PM EDT. Market Open.

Key Events

Loading Chart for SPRC

9/21 12:03 PM

DELL

Previous Close 0.2480
Open 0.2480
Bid 0.2454 x 100
Ask 0.2477 x 100
Day's Range 0.2404 - 0.2616
52 Week Range 0.2400 - 14.2200
Volume 2,384,868
Avg. Volume 3,747,317
Market Cap (intraday) 2.556M
Beta (5Y Monthly) 1.10
PE Ratio (TTM) --
EPS (TTM) -14.4300
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

3

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc secures final approval in Israel to start Tourette’s Syndrome trial

SciSparc secures final approval in Israel to start Tourette’s Syndrome trial

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SPRC

94.94%

S&P 500

20.19%

1-Year Return

SPRC

93.88%

S&P 500

32.17%

3-Year Return

SPRC

99.84%

S&P 500

28.67%

5-Year Return

SPRC

99.83%

S&P 500

26.58%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

0.2468

-0.48%

Mkt Cap 2.556M

Industry Biotechnology

PaxMedica, Inc.

0.1100

-4.35%

Mkt Cap 1.197M

Industry Biotechnology

Revelation Biosciences, Inc.

0.7966

+4.66%

Mkt Cap 2.994M

Industry Biotechnology

Psyence Biomedical Ltd.

0.1165

-2.92%

Mkt Cap 1.945M

Industry Biotechnology

0.2000

-7.83%

Mkt Cap 1.078M

Industry Biotechnology

Windtree Therapeutics, Inc.

2.6700

-7.93%

Mkt Cap 4.301M

Industry Biotechnology

Lipella Pharmaceuticals Inc.

0.4789

+6.19%

Mkt Cap 3.881M

Industry Biotechnology

Cardio Diagnostics Holdings, Inc.

0.2481

-5.73%

Mkt Cap 5.974M

Industry Biotechnology

Biodexa Pharmaceuticals Plc

0.2695

-9.87%

Mkt Cap 3.913M

Industry Biotechnology

Elevai Labs Inc.

0.0894

-14.87%

Mkt Cap 1.86M

Industry Biotechnology

Clearmind Medicine Inc.

1.2309

+0.89%

Mkt Cap 4.993M

Industry Biotechnology

Valuation Measures

    Annual 

As of 9/25/2024

Market Cap

2.57M
Enterprise Value

-2.43M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

0.04
Price/Book (mrq)

0.34
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-177.91%
Return on Assets (ttm)

-33.12%
Return on Equity (ttm)

-73.37%
Revenue (ttm)

2.88M
Net Income Avi to Common (ttm)

-5.12M
Diluted EPS (ttm)

-14.4300

Balance Sheet and Cash Flow

Total Cash (mrq)

5.08M
Total Debt/Equity (mrq)

0.79%
Levered Free Cash Flow (ttm)

-5.92M

SPRC does not have Company Insights